| Dr Michele T Evans, PHD | |
|
6457 Reflections Dr Ste 120, Dublin, OH 43017-2352 | |
| (614) 792-1108 | |
| (614) 792-0018 |
| Full Name | Dr Michele T Evans |
|---|---|
| Gender | Female |
| Speciality | Clinical Psychologist |
| Experience | 19 Years |
| Location | 6457 Reflections Dr Ste 120, Dublin, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073718060 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | 6316 (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lewis And Evans Llc | 1557600251 | 7 |
News Archive
Australian researchers have found a new drug target for stopping the spread of malaria, after successfully blocking the world's deadliest malaria parasite - Plasmodium falciparum - from completing the 'transmission stage' of its lifecycle.
Reflecting the increased need for medical practices and healthcare facilities to streamline patient record processes in order to increase efficiency across a range of insurance and billing functions, Canon U.S.A., Inc., a leader in digital imaging, will showcase an array of workflow simplifying solutions from its innovative imageFORMULA document scanning portfolio, including the new ScanFront 300P network scanner, at the Medical Group Management Association (MGMA) 2010 Annual Conference, October 24-27, 2010 at the Ernest N. Morial Convention Center in New Orleans.
A consortium of thirty-two researchers worldwide, led by Dr Jordi Surrallés, professor of the Department of Genetics and Microbiology at Universitat Autònoma de Barcelona (UAB) and member of the Centre for Biomedical Network Research on Rare Diseases (CIBERER), genetically and clinically characterised almost all Spanish patients suffering from Franconi anaemia, a rare disease affecting one in every 500,000 persons and which is characterised by severe anaemia in children, congenital malformations and a high predisposition to cancer.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.
› Verified 1 days ago
| Entity Name | Psychology Consultants Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205882941 PECOS PAC ID: 2163310475 Enrollment ID: O20040309000096 |
News Archive
Australian researchers have found a new drug target for stopping the spread of malaria, after successfully blocking the world's deadliest malaria parasite - Plasmodium falciparum - from completing the 'transmission stage' of its lifecycle.
Reflecting the increased need for medical practices and healthcare facilities to streamline patient record processes in order to increase efficiency across a range of insurance and billing functions, Canon U.S.A., Inc., a leader in digital imaging, will showcase an array of workflow simplifying solutions from its innovative imageFORMULA document scanning portfolio, including the new ScanFront 300P network scanner, at the Medical Group Management Association (MGMA) 2010 Annual Conference, October 24-27, 2010 at the Ernest N. Morial Convention Center in New Orleans.
A consortium of thirty-two researchers worldwide, led by Dr Jordi Surrallés, professor of the Department of Genetics and Microbiology at Universitat Autònoma de Barcelona (UAB) and member of the Centre for Biomedical Network Research on Rare Diseases (CIBERER), genetically and clinically characterised almost all Spanish patients suffering from Franconi anaemia, a rare disease affecting one in every 500,000 persons and which is characterised by severe anaemia in children, congenital malformations and a high predisposition to cancer.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.
› Verified 1 days ago
| Entity Name | Lewis And Evans Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407310576 PECOS PAC ID: 1557600251 Enrollment ID: O20190225000445 |
News Archive
Australian researchers have found a new drug target for stopping the spread of malaria, after successfully blocking the world's deadliest malaria parasite - Plasmodium falciparum - from completing the 'transmission stage' of its lifecycle.
Reflecting the increased need for medical practices and healthcare facilities to streamline patient record processes in order to increase efficiency across a range of insurance and billing functions, Canon U.S.A., Inc., a leader in digital imaging, will showcase an array of workflow simplifying solutions from its innovative imageFORMULA document scanning portfolio, including the new ScanFront 300P network scanner, at the Medical Group Management Association (MGMA) 2010 Annual Conference, October 24-27, 2010 at the Ernest N. Morial Convention Center in New Orleans.
A consortium of thirty-two researchers worldwide, led by Dr Jordi Surrallés, professor of the Department of Genetics and Microbiology at Universitat Autònoma de Barcelona (UAB) and member of the Centre for Biomedical Network Research on Rare Diseases (CIBERER), genetically and clinically characterised almost all Spanish patients suffering from Franconi anaemia, a rare disease affecting one in every 500,000 persons and which is characterised by severe anaemia in children, congenital malformations and a high predisposition to cancer.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.
› Verified 1 days ago
| Entity Name | Doctor On Demand Professionals P C |
|---|---|
| Entity Type | Part B Supplier - Other |
| Entity Identifiers | NPI Number: 1174931448 PECOS PAC ID: 9436464567 Enrollment ID: O20200515000675 |
News Archive
Australian researchers have found a new drug target for stopping the spread of malaria, after successfully blocking the world's deadliest malaria parasite - Plasmodium falciparum - from completing the 'transmission stage' of its lifecycle.
Reflecting the increased need for medical practices and healthcare facilities to streamline patient record processes in order to increase efficiency across a range of insurance and billing functions, Canon U.S.A., Inc., a leader in digital imaging, will showcase an array of workflow simplifying solutions from its innovative imageFORMULA document scanning portfolio, including the new ScanFront 300P network scanner, at the Medical Group Management Association (MGMA) 2010 Annual Conference, October 24-27, 2010 at the Ernest N. Morial Convention Center in New Orleans.
A consortium of thirty-two researchers worldwide, led by Dr Jordi Surrallés, professor of the Department of Genetics and Microbiology at Universitat Autònoma de Barcelona (UAB) and member of the Centre for Biomedical Network Research on Rare Diseases (CIBERER), genetically and clinically characterised almost all Spanish patients suffering from Franconi anaemia, a rare disease affecting one in every 500,000 persons and which is characterised by severe anaemia in children, congenital malformations and a high predisposition to cancer.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michele T Evans, PHD 6457 Reflections Dr Ste 120, Dublin, OH 43017-2352 Ph: (614) 792-1108 | Dr Michele T Evans, PHD 6457 Reflections Dr Ste 120, Dublin, OH 43017-2352 Ph: (614) 792-1108 |
News Archive
Australian researchers have found a new drug target for stopping the spread of malaria, after successfully blocking the world's deadliest malaria parasite - Plasmodium falciparum - from completing the 'transmission stage' of its lifecycle.
Reflecting the increased need for medical practices and healthcare facilities to streamline patient record processes in order to increase efficiency across a range of insurance and billing functions, Canon U.S.A., Inc., a leader in digital imaging, will showcase an array of workflow simplifying solutions from its innovative imageFORMULA document scanning portfolio, including the new ScanFront 300P network scanner, at the Medical Group Management Association (MGMA) 2010 Annual Conference, October 24-27, 2010 at the Ernest N. Morial Convention Center in New Orleans.
A consortium of thirty-two researchers worldwide, led by Dr Jordi Surrallés, professor of the Department of Genetics and Microbiology at Universitat Autònoma de Barcelona (UAB) and member of the Centre for Biomedical Network Research on Rare Diseases (CIBERER), genetically and clinically characterised almost all Spanish patients suffering from Franconi anaemia, a rare disease affecting one in every 500,000 persons and which is characterised by severe anaemia in children, congenital malformations and a high predisposition to cancer.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.
› Verified 1 days ago
Dr. Guy P Rowinski, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 6099 Riverside Dr Ste 100, Dublin, OH 43017 Phone: 614-615-1000 | |
Todd M Kays, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 94 N High St, Suite 200, Dublin, OH 43017 Phone: 614-874-0178 Fax: 614-874-0179 | |
Stephanie Danner, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 5828 Garden Hill Ln, Dublin, OH 43017 Phone: 614-905-9192 | |
Dr. Chiaothong Yong, PSYD Psychologist Medicare: Accepting Medicare Assignments Practice Location: 6790 Perimeter Dr Ste 200, Dublin, OH 43016 Phone: 614-685-4614 | |
Dr. Kayla Brooke Lee, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 5181 Mansell St Apt 303, Dublin, OH 43016 Phone: 614-795-3370 | |
Patricia Perry, PSYD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 6465 Reflections Dr Ste 110, Dublin, OH 43017 Phone: 614-792-1132 |